Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

373.00INR
11:20am BST
Change (% chg)

Rs1.25 (+0.34%)
Prev Close
Rs371.75
Open
Rs373.60
Day's High
Rs378.00
Day's Low
Rs371.10
Volume
711,671
Avg. Vol
2,292,801
52-wk High
Rs515.00
52-wk Low
Rs332.75

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Gets Zero 483 Observations For Ahmedabad Plant
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Cadila Healthcare Ltd ::SAYS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA.SAYS AHMEDABAD PLANT HAD COMPLETED USFDA AUDIT FROM 14TH AUGUST TO 24TH AUGUST 2018 WITH ZERO 483 OBSERVATIONS.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval For Risedronate Sodium Delayed-Release Tablets
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR RISEDRONATE SODIUM DELAYED-RELEASE TABLETS.SAYS TABLETS WILL BE MANUFACTURED AT GROUP’S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Got USFDA Nod For Acyclovir Sodium Injection
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR ACYCLOVIR SODIUM INJECTION.SAYS DRUG WILL BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.SAYS ACYCLOVIR INJECTION IS USED TO TREAT SEVERE INFECTIONS CAUSED BY HERPES VIRUSES.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Approval For Gemfibrozil, Aripiprazole Tablets
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR GEMFIBROZIL TABLETS AND ARIPIPRAZOLE ORALLY DISINTEGRATING TABLETS.BOTH DRUGS WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.  Full Article

India's Cadila Healthcare June Qtr Consol Profit Surges
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Cadila Healthcare Ltd ::JUNE QUARTER CONSOL NET PROFIT 4.61 BILLION RUPEES VERSUS PROFIT OF 1.38 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL NET PROFIT WAS 4.40 BILLION RUPEES.JUNE QUARTER CONSOL SALES 27.69 BILLION RUPEES VERSUS 21.55 BILLION RUPEES LAST YEAR.  Full Article

Cadila Healthcare Says Zydus Got USFDA Nod For Azithromycin For Oral Suspension USP
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR AZITHROMYCIN FOR ORAL SUSPENSION USP.DRUG USED TO TREAT DIFFERENT TYPES OF BACTERIAL INFECTIONS; WILL BE MANUFACTURED AT CO'S FORMULATIONS MANUFACTURING FACILITY AT BADDI.  Full Article

Cadila Healthcare says Zydus Received Tentative Approval From USFDA For Vardenafil
Monday, 30 Jul 2018 

July 30 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD - ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR VARDENAFIL HYDROCHLORIDE TABLETS USP.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Piroxicam Capsules
Thursday, 19 Jul 2018 

July 19 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR PIROXICAM CAPSULES USP.DRUG WILL BE MANUFACTURED AT GROUP'S MANUFACTURING FACILITY AT SEZ, AHMEDABAD.DRUG INDICATED FOR SYMPTOMATIC TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS.  Full Article

India's Cadila Healthcare Says Zydus Gets 4 ANDA Approvals From U.S FDA
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FOUR CONSECUTIVE ANDA APPROVALS FROM U.S FDA.SAYS PRODUCTS WILL BE MANUFACTURED AT THE GROUP'S MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.APPROVALS TO MARKET OLANZAPINE TABLETS, GLIPIZIDE EXTENDED-RELEASE TABLETS, VORICONAZOLE FOR INJECTION,FLUOCINONIDE TOPICAL SOLUTION.  Full Article

Cadila Healthcare Says Zydus Gets Final Nod From U.S. FDA For Clindamycin Phosphate Topical Solution
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR CLINDAMYCIN PHOSPHATE TOPICAL SOLUTION USP.DRUG USED TO TREAT ACNE, HELPS TO DECREASE THE NUMBER OF ACNE LESIONS.DRUG TO BE MANUFACTURED AT TOPICAL MANUFACTURING FACILITY AT AHMEDABAD.  Full Article